Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

_______________ As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­­mote arrange­ments? (MM&M): “San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed…

Read More

Neuroimaging as a marketing tool: Key Neurotech Patent #2

As men­tioned, we are fea­tur­ing a foun­da­tion­al Per­va­sive Neu­rotech patent a day, from old­er to new­er by issue date. Today we are shar­ing a 2000 patent assigned to The Nielsen Com­pa­ny. U.S. Patent No. 6,099,319: Neu­roimag­ing as a mar­ket­ing tool Assignee(s): The Nielsen Com­pa­ny Inventor(s): Ger­ald Zalt­man, Stephen M. Koss­lyn Tech­nol­o­gy Cat­e­go­ry: Hybrid Issue Date: August 8, 2000 SharpBrains’…

Read More

Brain training franchisor LearningRx settles FTC complaint about its marketing claims

Learn­ingRx To Pay $200K For Alleged­ly Unproven Claims That Brain Train­ing Can Improve Income, Treat Autism & ADHD (Con­sumerist): “The com­pa­ny behind the Learn­ingRX “brain train­ing” pro­gram has agreed to pay a $200,000 set­tle­ment and to stop mak­ing claims that its sys­tem is clin­i­cal­ly proven to treat seri­ous health con­di­tions, or that it can 

Read More